Pfizer stock gains 2.35% as new products lift 2026 outlook
Published on 11/05/2026 at 16:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth Beyond COVID Supports Outlook
- Launched and acquired products grew 32% operationally in the third quarter.
- Pfizer raised its 2026 revenue and adjusted earnings outlook after stronger year-to-date performance.
- Research spending and late-stage pipeline milestones remain central to the company's growth plan.
Pfizer's third-quarter results added a new operating detail to the company's effort to replace declining COVID product sales: revenue from launched and acquired products grew 32% operationally and contributed USD 3.8 billion to quarterly revenue of USD 16.6 billion. Pfizer raised its full-year outlook after the November 3 results.
The company now expects 2026 revenue of USD 62.0 billion to USD 64.0 billion and adjusted diluted earnings per share of USD 2.95 to USD 3.05. The guidance update followed stronger year-to-date performance and continued commercial discipline, according to Pfizer.
Newer Products Carry More Weight
Pfizer said medicines for blood clots, cancer and migraine were important contributors during the quarter. The company also highlighted progress across its late-stage pipeline, including two regulatory decisions, one pivotal readout and eight pivotal study starts since the previous quarterly earnings update.
Research and development spending reached USD 8.3 billion in the first nine months of 2026 across oncology, vaccines, inflammation and immunology, and internal medicine. That investment gives investors a second measure of the company's transition beyond COVID products, although the commercial contribution of newer medicines remains the immediate focus.
Pfizer Stock Holds Above Xetra Close
Pfizer stock traded at EUR 27.83 on Lang & Schwarz at 16:38 CET on Thursday, November 5, 2026, 2.35 percent above the Xetra close of Wednesday, November 4, at EUR 27.19. Yahoo Finance showed the Xetra listing in euros at the November 4 close; the current Lang & Schwarz price is the latest available before the Xetra session cutoff.
Investors can follow the real-time quote of Pfizer stock while assessing whether growth from newer products can offset further COVID-related declines.
Pfizer Inc. at a glance
- Company: Pfizer Inc.
- ISIN: US7170811035
- Lang & Schwarz price: EUR 27.83 at 16:38 CET on November 5, 2026
- Change versus Xetra close: 2.35% above EUR 27.19 on November 4, 2026
Broader sentiment can be followed in the S&P 500 market reports.
More results, pipeline updates and analysis are available in more news and analyses on Pfizer stock.
